NCT05655299

VTX958 Versus Placebo for the Treatment of Moderate to Severe Psoriasis

A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of VTX958 in Participants With Moderate to Severe Psoriasis

• Status: Terminated
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 222 (actual)
• Sponsor: Ventyx Biosciences, Inc · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This is a study to understand if taking VTX958 is safe and effective in participants diagnosed with moderate to severe psoriasis (PsO). Approximately 200 patients will take VTX958 Dose A, VTX958 Dose B, VTX958 Dose C, VTX958 Dose D, or placebo. The study consists of a 30-day Screening Period (to see if a participant qualifies for the study), a 16-week double-blind period (a participant receives active Dose A, Dose B, Dose C, Dose D, or placebo), a 16-week Long Term Extension (LTE) period, a 36-week Open Label Extension (OLE) period and a 4-week Follow-Up Period. The maximal duration of treatment will be approximately 16 months.

Conditions

• Psoriasis

Interventions

Type	Name	Description
DRUG	VTX958 Dose A	Dose A
DRUG	VTX958 Dose B	Dose B
DRUG	VTX958 Dose C	Dose C
DRUG	VTX958 Dose D	Dose D
DRUG	Placebo	Placebo

Timeline

• Start date: 2022-11-17
• Primary completion: 2023-09-25
• Completion: 2023-12-20
• First posted: 2022-12-19
• Last updated: 2024-09-19

Locations

63 sites across 3 countries: United States, Canada, Poland

Regulatory

• FDA-regulated drug study